Effects of oversulfated and fucosylated chondroitin sulfates on coagulation: Challenges for the study of anticoagulant polysaccharides

Thrombosis and Haemostasis

Volumn 103, Issue 5, 2010, Pages 994-1004

  Fonseca, Roberto J C ^a   Oliveira, Stephan Nicollas M C G ^a   Pomin, Vitor H ^a   Mecawi, André S ^a   Araujo, Iracema G ^a   Mourão, Paulo A S ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antithrombotic drugs; Heparin; Kallikrein system; Sulfated polysaccharides

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 12; CHONDROITIN SULFATE; FUCOSYLCHONDROITIN SULFATE; KALLIKREIN; PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; FUCOSYLATED CHONDROITIN SULFATE; HEPARIN; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERIAL PRESSURE; ARTICLE; BLOOD CLOTTING; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HEART RATE; HYPOTENSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; RAT; VEIN THROMBOSIS; AFFINITY CHROMATOGRAPHY; ANIMAL; BLOOD; BLOOD PRESSURE; BOVINAE; CHEMICALLY INDUCED; CHEMISTRY; COMPARATIVE STUDY; DOG; DRUG EFFECTS; HORSE; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PARTIAL THROMBOPLASTIN TIME; VENOUS THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PRESSURE; CATTLE; CHONDROITIN SULFATES; CHROMATOGRAPHY, AFFINITY; DOGS; FACTOR XII; HEPARIN; HORSES; HUMANS; MODELS, ANIMAL; PARTIAL THROMBOPLASTIN TIME; RATS; THROMBOPLASTIN; VENOUS THROMBOSIS;

EID: 77952087454     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-10-0734     Document Type: Article

References (34)

1. Crafoord C, Jorpes E. Heparin as a prophylactic against thrombosis. J Am Med Assoc 1941; 116: 2831-2842.
2. Ryckelynck JP, Chouraqui D, Lobbedez T. Anticoagulation of the extracorporeal circuit in chronic hemodialysis. Nephrologie 1998; 19: 223-225. (Pubitemid 28294455)
3. Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 9: 225-232.
4. Mourão PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Design 2004; 10: 967-981.
5. Borris LC. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag 2008; 4: 855-862.
6. Henry BL, Desai UR. Recent research developments in the direct inhibition of coagulation proteinases--inhibitors of the initiation phase. Cardiovasc Hematol Agents Med Chem 2008; 6: 323-336.
7. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008; 34: 39-57. (Pubitemid 351640881)
8. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467. (Pubitemid 351793019)
9. Pereira MS, Melo FR, Mourão PAS. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans? Glycobiology 2002; 12: 573-580.
10. Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26: 669-675. (Pubitemid 351824692)
11. Vieira RP, Mulloy B, Mourão PAS. Structure of a fucose-branched chondroitin sulfate from sea cucumber: evidence for the presence of 3-O-sulfo-β-D-glucuronosyl residues. J Biol Chem 1991; 266: 13530-13536. (Pubitemid 21907381)
12. Mourão PAS, Pereira MS, Pavão MSG, et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm: sulfated fucose branches on the polysaccharide account for its high anticoagulant activity J Biol Chem 1996; 271: 23973-23984.
13. Pacheco RG, Vicente CP, Zancan P, Mourão PAS. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coag Fibrin 2000; 11: 563-573.
14. Maruyama T, Toida T, Imanari T, et al. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res. 1998; 306: 35-43. (Pubitemid 28304973)
15. Melo FR, Pereira MS, Foguel D, et al. Antithrombin-mediated anticoagulant activity of sulfated polysaccharides: different mechanisms for heparin and sulfated galactans. J Biol Chem 2004; 279: 20824-20835.
16. Farndale RW, Buttle DJ, Barret AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986; 883: 173-177.
17. Fonseca RJ, Oliveira SN, Melo FR, et al. Slight differences in sulfation of algal galactans account for differences in their anticoagulant and venous antithrombotic activities. Thromb Haemost 2008; 99: 539-545.
18. Melo FR, Mourão PAS. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases. Thromb Haemost 2008; 99: 531-538.
19. Wessler S, Reimer SM, Sheps MC. Biologic assay of thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-946.
20. Beeler D, Rosenberg R, Jordan R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-2913. (Pubitemid 9196125)
21. Olson ST, Shore JD. Binding of high affinity heparin to antithrombin III. Characterization of the protein fluorescence enhancement. J Biol Chem 1981; 256: 11065-11072. (Pubitemid 12181590)
22. Glauser BF, Pereira MS, Monteiro RQ, Mourão PAS. Serpin-independent anti-coagulant activity of a fucosylated chondroitin sulfate. Thromb Haemost 2008; 100: 420-428.
23. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209. (Pubitemid 34158283)
24. Alban S, Lühn S. Prothrombin time for detection of contaminated heparins. N Engl J Med 2008; 359: 2732-2734.
25. Melo FR, Pereira MS, Monteiro RQ, et al. Sulfated galactan is a catalyst of antithrombin- mediated inactivation of alpha-thrombin. Biochim Biophys Acta 2008; 1780: 1047-1053.
26. Jeske WP, Walenga JM, Adiguzel C, et al. Structural and functional characterization of low molecular weight heparins: Impact on the development of guidelines for generic products at www.natfonline.org/ethrombosis, 2009.
27. Li B, Suwan J, Martin JG, et al. Oversulfated chondroitin sulfate interact with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol 2009; 78: 292-300.
28. Gozzo AJ, Nues VA, Carmona AK, et al. Glycosaminoglycans affect the action of human plasma kallikrein on kininogen hydrolysis and inflammation. Immunopharmacology 2002; 2: 1861-1865.
29. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175: 3377-3385. (Pubitemid 41170560)
30. Fonseca RJC, Mourão PAS. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
31. Beyer T, Diehl B, Randel G, et al. Quality assessment of unfractionated heparin using 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 2008; 48: 13-19.
32. Tami C, Puig M, Reepmeyer JC, et al. Inhibition of Taq polymerase as a method for screening heparin for oversulfated contaminants. Biomaterials 2008; 29: 4808-4814.
33. Sitkowski J, Bednarek E, Bocian W, et al. Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem 2008; 51: 7663-7665.
34. Domanig R, Jöbstl W, Gruber S, et al. One-dimensional cellulose acetate plate electrophoresis-A feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin. J Pharm Biomed Anal 2009; 49: 151-155.